Formulation Brief & Sample Request Guide for Barrier Repair & Sensitive Skin

Key Technical Parameters #

Barrier repair is one of the most technically constrained categories we work in. The ingredient list is usually short, the claims are sensitive-adjacent, and the margin for formulation error is low — because the target consumer is already compromised. Brand founders who come to us with a solid brief get to lab samples in 2–3 weeks. Those who don’t spend the first month answering questions we should have had on day one. This guide covers exactly what we need from you, how we evaluate what you send us, and what the path from brief to production batch actually looks like.

The Spec That Drives Everything: Your Target Consumer’s Skin Condition #

Before we talk ingredients or textures, we need to know the condition of the skin you’re formulating for. Not just “sensitive” — that word covers a lot of ground. Reactive-barrier-deficient skin behaves very differently from post-procedure skin, and a formula optimized for one can actively aggravate the other.

Here’s a concrete example. A brand briefed us on a “sensitive skin moisturizer” targeting mature consumers in the UK. We assumed mild barrier compromise. What they meant was post-retinol use, nightly, with existing redness. Those are completely different design targets — different occlusive levels, different fragrance thresholds (we run our own RIFM-aligned screening per our internal QC-F14 sensitization checklist), different pH tolerance, and different preservative choices.

The EU Cosmetics Regulation 1223/2009 doesn’t define “sensitive skin” as a regulatory category — it’s a consumer claim. That means the substantiation burden lands on your formulation brief, not on a regulatory filing. Your brief is where you tell us who this consumer is, what the skin state is, and what outcome they need.

What we ask in our intake form:

• Primary skin concern: compromised barrier, reactive/redness-prone, post-treatment, atopic-adjacent
• Age range of target consumer (this changes emollient selection significantly)
• Target geography and sales channel (EU retail has different preservative expectations than US DTC, and vastly different expectations than NMPA-registered products for China)
• Any specific claimed benefits you intend to make on-pack

That last point matters more than people expect. “Clinically tested on sensitive skin” and “dermatologist-tested” and “suitable for eczema-prone skin” all have different substantiation needs, and some require specific study designs we need to plan for from day one, not after sample approval.

Writing a Brief We Can Actually Use #

A good formulation brief for barrier repair and sensitive skin products has five components. Most brands submit two or three. The ones that get skipped are usually the ones that cause problems later.

1. Target texture and application format. “Lightweight moisturizer” isn’t enough. Tell us: cream, lotion, or gel-cream? Silicone-feel or no? Melts in or sits on? Rubs in within 30 seconds or is a longer absorption acceptable? We use a 5-point internal texture descriptor scale on all early samples, and we need your benchmark to calibrate to.

2. Benchmark product. Send us a physical reference if you have one. Photos of packaging don’t help. Even a half-used tube tells us more about target viscosity, skin feel, and finish than three paragraphs of description. If you don’t have a benchmark, point us to a publicly available product and tell us what you’d change.

3. Ingredient inclusions. Which actives are non-negotiable? We’ve seen briefs that list 11 “must-have” ingredients, and seven of them are incompatible at the concentrations suggested. Be prepared to have a conversation about which two or three are actually driving your claims.

4. Ingredient exclusions. This is where briefs get specific fast. Fragrance-free is common. Silicone-free is frequent. Paraben-free is now nearly universal in the briefs we receive. Some clients exclude PEG-derived emulsifiers entirely. Know your list and state it clearly. If you’re selling into EU and making a “clean” claim, we’ll cross-reference against SCCS Scientific Opinions on any borderline ingredients before prototyping.

5. Target price-per-unit at production volume. Formulation development and per-unit cost are different conversations, but they aren’t separate. If your target retail price is $18 and you need a 50ml product, working backwards to a $1.80–2.20 per-unit target constrains what actives we can put in at what concentrations. We need to know this upfront — not after we’ve developed a formula with 3% niacinamide, 1% ceramide complex, and a 0.5% centella extract and you tell us the cost is too high.

Supplier Qualification: What We Evaluate Before You See a Sample #

We run every prototype through a pre-stability screening before we give you a physical sample. For barrier-repair formulas specifically, the screening covers four things.

First, pH. Barrier-repair products typically sit at pH 5.0–6.0 to align with the skin’s natural acid mantle. We confirm this on every batch, and if your formula contains buffering agents that drift, we catch it here. Drift beyond ±0.3 pH units over four weeks at 40°C is a flag we take seriously.

Second, preservative challenge testing against ICH Stability Guidelines protocol baselines. For sensitive skin products, we almost always lean toward phenoxyethanol/ethylhexylglycerin combinations at 0.8–1.0% rather than the more aggressive preservative systems, and we need to confirm the challenge results hold at the formula’s pH before we ship you a sample.

Third, skin-feel panel. We run a five-person internal spread panel on all new prototypes, rating immediate feel, 15-minute absorption, and 60-minute residue. This isn’t a clinical test — it’s a development filter. It tells us whether a formula is in the right direction before we commit to 8 weeks of accelerated stability.

Fourth — and this is where things often get interesting — compatibility with the packaging you’re planning. We’ve had formulas that performed perfectly in glass jars but showed visible phase separation after 12 weeks in an airless pump with a PP inner, because a particular emollient was migrating into the polymer. Ask your OEM about this before you finalize packaging.

On the clinical side: a 2022 randomized, double-blind split-face study (n=46, 8 weeks) using a ceramide-niacinamide barrier cream formulation showed a 34% reduction in TEWL versus vehicle control at week 8. We reference this in category development because it illustrates the measurable, quantifiable endpoint barrier products can achieve — and it sets a benchmark for the kind of independent testing your brand should plan for before making a TEWL-related claim.

Cost Structure and Timeline: From Brief to First Batch #

This is usually where the conversation gets uncomfortable, so we’d rather be direct about it.

Development fees. Many OEMs charge a one-time formulation development fee. Ours ranges from $500–$1,500 USD depending on formula complexity and number of revision rounds included. This covers the first three prototypes. Additional rounds are typically charged at a per-iteration rate. Some brands push back on development fees — and for high-volume projects, there’s usually room to discuss how the fee is structured. But waiving it entirely usually signals that the OEM is planning to recover the cost elsewhere.

Sample MOQ. For evaluation samples, we typically produce 5–10 units at lab scale (50–100g batches). There’s no per-unit price at this stage — the development fee covers material and labor. For stability samples, we scale to 500g batches, which is the minimum we consider predictive for manufacturing-scale behavior.

Production MOQ. For barrier-repair moisturizers and serums in tubes or jars, production MOQ is typically 3,000–5,000 units depending on packaging complexity. For airless pumps with a custom component, minimum is often 5,000 because of component MOQs upstream.

Timeline. This varies by formula complexity, but the structure we work to is: brief received and aligned → first prototypes in 2–3 weeks → revision rounds 1–2 weeks each → stability submission within week 6 → accelerated stability results (40°C/75%RH, 8 weeks) by week 14 → real-time stability initiated at week 6 and ongoing → production-ready formula confirmed post-stability → first production batch typically week 18–22 from brief alignment.

That’s four to five months for a clean run. Add a month if regulatory registration is required for the target market. Add another month if you need third-party clinical testing before launch.

Timeline assumes single target market and no novel actives requiring additional safety assessment.

The table above assumes things go smoothly. They don’t always. The most common delay we see is brands changing packaging after stability has started — which restarts the clock. Lock your packaging before stability begins.

We still haven’t worked out a clean internal process for managing late packaging changes without affecting timelines. Our current workaround is to run preliminary stability in two packaging formats simultaneously, but that doubles material costs. We’re not sure it’s the right trade-off for every project.

Formulation Notes for Brand Partners #

When you brief us on a barrier-repair or sensitive skin product, the first questions we ask are: what market is this for, what channel, and what are you actually claiming on-pack? Those three answers shape every formulation decision that follows — including preservative selection, pH range, and how much clinical support you’ll need at launch.

The most common mistake we see in briefs is over-specifying the ingredient list while under-specifying the consumer. We’ll receive a brief with eight required actives and a 15-item exclusion list, but no description of the target skin condition, no benchmark texture, and no price target. That forces us to make assumptions that cost revision rounds later. A better brief prioritizes the consumer problem first, then the ingredient constraints.

For our encapsulation technology applications within barrier formulations — particularly where you’re combining an active like niacinamide with a ceramide system — tell us early if encapsulation is on the table. It changes the emulsion architecture significantly and needs to be in the brief, not added at revision round two.

Lab samples: 2–3 weeks. Accelerated stability: 4–8 weeks. Real-time 24-month stability initiated concurrently from week 6. Plan for 18–22 weeks from brief to production-ready formula.

Frequently Asked Questions #

We want to add a benchmark product we like — can we just replicate it?
A: Not directly — reverse-engineering a competitor’s formula raises IP issues, and we won’t do a direct copy. What we can do is use it as a sensory and performance reference, then build a formula that achieves a comparable result through different means. That’s actually what most brands mean when they say “make something like this.”

What regulatory approvals do we need before going to market in the EU?
A: Cosmetics in the EU don’t require pre-market approval, but they do require a Cosmetic Product Safety Report, a Responsible Person in the EU, and compliance with EU Cosmetics Regulation 1223/2009. For sensitive skin claims, we’d also strongly recommend a dermatologist-tested study — not legally required, but expected by EU retail buyers and increasingly by regulators looking at substantiation. For the US, FDA Cosmetics Guidelines apply; for China, NMPA Cosmetic Regulation requires full registration, which adds 6–12 months and additional testing.

What actually goes wrong during stability? What should I watch for?
A: Sensitive-skin formulas with low preservative loads are the most vulnerable. We’ve seen pH drift of 0.5 units between week 4 and week 8 at 40°C in formulas that looked fine at week 2, which then failed preservative challenge on retest. The packaging incompatibility issue is the other one — specifically PP airless pumps and certain ester emollients. By the time you see it at week 12, your timeline is already off by six weeks.

What’s the minimum order to get started, and what does it actually cost?
A: Development fee is $500–$1,500 USD for the initial formulation. Evaluation samples are covered within that. First production run MOQ is typically 3,000–5,000 units, depending on packaging. Per-unit cost for a barrier moisturizer in a 50ml format ranges quite a bit depending on actives load — we’d rather quote you once we’ve aligned on the formula than give you a number that changes later.

Should I finalize packaging before or after formula approval?
A: Before. This surprises a lot of founders, but packaging selection affects stability protocol, preservative selection, and sometimes the emulsion type. We’ve had to reformulate after packaging was changed post-stability because the new container had a different inner material. Lock your packaging format — tube, jar, airless, or pump — before we submit for stability. You can finalize aesthetics later, but the container material and closure need to be confirmed early.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.